Teva Pharmaceutical Industries (NYSE:TEVA) Given New $28.00 Price Target at Barclays

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target upped by Barclays from $25.00 to $28.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other equities research analysts have also recently issued research reports about the company. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.

Teva Pharmaceutical Industries Trading Up 3.7 %

TEVA opened at $22.09 on Wednesday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a fifty-two week low of $10.34 and a fifty-two week high of $22.17. The company’s 50 day moving average price is $17.79 and its two-hundred day moving average price is $17.51. The firm has a market capitalization of $25.03 billion, a price-to-earnings ratio of -25.99, a PEG ratio of 0.99 and a beta of 0.79.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TEVA. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth approximately $188,000. Coronation Fund Managers Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $1,334,000. Raymond James & Associates lifted its holdings in Teva Pharmaceutical Industries by 5.1% during the second quarter. Raymond James & Associates now owns 815,944 shares of the company’s stock worth $13,259,000 after acquiring an additional 39,610 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Teva Pharmaceutical Industries by 69.8% during the second quarter. Allspring Global Investments Holdings LLC now owns 62,410 shares of the company’s stock worth $1,014,000 after acquiring an additional 25,657 shares during the period. Finally, Summit Securities Group LLC purchased a new position in Teva Pharmaceutical Industries in the second quarter worth $366,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.